Neurology | Page 62 of 79 | Links Medicus Content Curation & Alerts in Medicine

“Observational study: Incidence of EPSs with antidepressants. RRs: duloxetine, 5.68; mirtazapine, 3.78; citalopram, 3.47; escitalopram, 3.23; paroxetine, 3.07; sertraline, 2.57; venlafaxine, 2.37; bupropion, 2.31; and fluoxetine, 2.03 (all significant)” (via @psychopharmacol see Tweet)

Perspective: Sleep Disorders Associated With Alzheimer’s Disease

22 Jun, 2018 | 02:17h | UTC

Sleep Disorders Associated With Alzheimer’s Disease: A Perspective – Frontiers in Neuroscience (free)

Position Paper: Treatment of Nightmare Disorder in Adults

18 Jun, 2018 | 23:01h | UTC

Position Paper for the Treatment of Nightmare Disorder in Adults: An American Academy of Sleep Medicine Position Paper – Journal of Clinical Sleep Medicine (free)

Commentary: New position paper recommends treatment options for nightmare disorder in adults – American Academy of Sleep Medicine, via EurekAlert (free)

Report: Current Endovascular Strategies for Cerebral Venous Thrombosis

18 Jun, 2018 | 09:15h | UTC

Current endovascular strategies for cerebral venous thrombosis: report of the SNIS Standards and Guidelines Committee – Journal of Neurointerventional Surgery (free)

Guideline: Efficacy and Tolerability of the New Antiepileptic Drugs

18 Jun, 2018 | 00:21h | UTC

Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs – American Academy of Neurology and the American Epilepsy Society

Part I: Treatment of new-onset epilepsy (free PDF)

Part II: Treatment-resistant epilepsy (free PDF)

Commentary: New Epilepsy Guidelines Shed Light on Explosion of New Drugs – MedPage Today (free registration required)

Cohort Study: High Blood Pressure in 50-year-olds Associated with Higher Risk of Dementia

15 Jun, 2018 | 02:13h | UTC

Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension – European Heart Journal (free)

Commentaries: Dementia risk increased in 50-year-olds with blood pressure below hypertension threshold – European Society of Cardiology, via EurekAlert (free) AND Blood pressure below treatable threshold linked to heightened dementia risk – OnMedica (free) AND Studies: Higher blood pressure increases risk for dementia – UPI (free) AND High Blood Pressure at Age 50 Tied to Dementia Risk – The New York Times (10 articles per month are free) AND Dementia risk to 50-year-olds with raised blood pressure – study – The Guardian (free)

Review: Antiepileptic Drugs in Critically Ill Patients

15 Jun, 2018 | 02:05h | UTC

Antiepileptic drugs in critically ill patients – Critical Care (free)

Randomized Trial: Antipsychotic Treatment of Very Late-onset Schizophrenia-like Psychosis

15 Jun, 2018 | 00:55h | UTC

Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial – The Lancet Psychiatry (free)

Commentaries: Very late-onset schizophrenia-like psychosis: positive findings but questions remain unanswered – The Lancet Psychiatry (free) AND Low-Dose Antipsychotic Effective in Late-Onset Psychosis – Medscape (free registration required) AND Low-dose amisulpride effective for late-onset psychosis – Healio (free registration required)

Randomized Trial Continuous Low-dose Antibiotic Prophylaxis to Prevent UTI in Adults who Perform Clean Intermittent Self-catheterization

7 Jun, 2018 | 02:52h | UTC

Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: the AnTIC RCT – Health Technology Assessment (free)

“The results of this large randomised trial, conducted in accordance with best practice, demonstrate clear benefit for antibiotic prophylaxis in terms of reducing the frequency of UTI for people carrying out CISC”.

Systematic Review: Exercise for Cognitive Brain Health in Aging

7 Jun, 2018 | 02:43h | UTC

Exercise for cognitive brain health in aging: A systematic review for an evaluation of dose – Neurology Clinical Practice (link to abstract – $ for full-text)

Commentary: How Much Exercise Is Needed to Help Improve Thinking Skills? – American Academy of Neurology, via NewsWise (free) AND Exercise regimen can maintain cognition in older adults, researchers say – UPI (free) AND 1-Hour Exercise, 3 Times a Week Boosts Cognition in Older Adults – MedPage Today (free registration required)

Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders

7 Jun, 2018 | 02:37h | UTC

Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders – JAMA Neurology (free for a limited period)

Review: Perimesencephalic Hemorrhage

6 Jun, 2018 | 21:35h | UTC

Perimesencephalic Hemorrhage: A Review of Epidemiology, Risk Factors, Presumed Cause, Clinical Course, and Outcome – Stroke (free for a limited period)

Review: Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

6 Jun, 2018 | 21:26h | UTC

History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy – Mayo Clinic Proceedings (free)

Systematic Review: Effects of Physical Exercise on Cognitive Function in Parkinson’s Disease

29 May, 2018 | 18:36h | UTC

Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: A systematic review of randomized controlled trials of the last 10 years – PLOS One (free)

Randomized Trial: New Treatment for Prevention of Episodic Migraine Assessed

29 May, 2018 | 18:30h | UTC

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: Fremanezumab effective in preventing episodic migraine – 2 Minute Medicine (free)

“Among patients with episodic migraine in whom multiple medication classes had not previously failed, subcutaneous fremanezumab, compared with placebo, resulted in a statistically significant 1.3- to 1.5-day reduction in the mean number of monthly migraine days over a 12-week period”. (from JAMA)

“The small effect size in terms of reduction in number of days with migraine dampens enthusiasm for this medication, though without head-to-head comparison against other prophylactics, this is hard to assess” (from 2 Minute Medicine)